TAO Synergies Inc.: Form 10-Q for the period ended Mar 31, 2025
Filed with the SEC on May 15, 2025 and accepted by EDGAR at May 15, 2025, 16:15 ET.
Management's discussion and analysis
As filed, 25,014 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes appearing elsewhere in this report. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk Factors” included elsewhere in this report and our Annual Report on Form 10-K for the year ended December 31, 2024.
The following discussion highlights our results of operations and the principal factors that have affected our financial condition as well as our liquidity and capital resources for the periods described, and provides information that management believes is relevant for an assessment and understanding of the statements of financial condition and results of operations presented herein. The following discussion and analysis are based on the unaudited financial statements contained in this report, which we have prepared in accordance with United States generally accepted accounting principles. You should read the discussion and analysis together with such financial statements and the related notes thereto.
Basis of Presentation
The unaudited financial statements for the three months ended March 31, 2025 and 2024 include a summary of our significant accounting policies and should be read in conjunction with the discussion below and our financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in the financial statements. All such adjustments are of a normal recurring nature.
Overview
We are a biopharmaceutical company with product candidates in pre-clinical and clinical development. We began operations in October 2012. We are principally focused on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease, which is in the clinical testing stage. We are also evaluating Bryostatin-1 for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.
Neurotrope, our predecessor company, had been a party to a technology license and services agreement with the original Blanchette Rockefeller Neurosciences Institute (which has been known as Cognitive Research Enterprises, Inc. since October 2016), and its affiliate NRV II, LLC, which we collectively refer to herein as “CRE,” pursuant to which we now have an exclusive non-transferable license to certain patents and technologies required to develop our proposed products. We were formed for the primary purpose of commercializing the technologies initially developed by BRNI for therapeutic applications for AD or other cognitive dysfunctions. These technologies have been under development by BRNI since 1999 and, until March 2013, had been financed through funding from a variety of non-investor sources (which include not-for-profit foundations, the NIH, which is part of the U.S. Department of Health and Human Services, and individual philanthropists). From March 2013 forward, development of the licensed technology has been funded principally through us in collaboration with CRE.
September 2024 Private Placement
On September 10, 2024, we entered into the Series C Purchase Agreement with the Series C Investors, pursuant to which we agreed to sell to the Series C Investors (i) in a registered direct offering, an aggregate of 1,793 shares of Series C Preferred Stock, initially convertible into up to 448,250 Registered Conversion Shares and (ii) in a concurrent private placement, an aggregate of 3,207 shares of Series C Preferred Stock, initially convertible into up to 801,750 Unregistered Conversion Shares as well as Series C Warrants to acquire up to an aggregate of 1,250,000 Series B Warrant Shares.
GP Nurmenkari Inc. acted as the Series C Placement Agent. In connection with the Series C Offering, pursuant to an Engagement Letter between the Company and the Series C Placement Agent, we agreed to pay the Series C Placement Agent (i) a cash fee equal to 7.0% of the gross proceeds from any sale of securities in the Series C Offering and (ii) warrants to purchase shares of Common Stock equal to 3.0% of the number of shares of Common Stock that the Series C Preferred Stock are initially convertible into, with an exercise price of $4.00 per share and a five-year term.
The terms of the Series C Preferred Stock are as set forth in the Series C Certificate of Designations, which was filed with the Secretary of State for the State of Delaware on September 12, 2024. The Series C Preferred Stock is convertible into Series C Conversion Shares at the election of the holder at any time at the Series C Conversion Price. The Series C Conversion Price is subject to customary adjustments for stock dividends, stock splits, reclassifications and the like, and subject to price-based adjustment in the event of any issuances of Common Stock, or securities convertible, exercisable or exchangeable for Common Stock, at a price below the then-applicable Series C Conversion Price (subject to certain exceptions). We are required to redeem the Series C Preferred Shares in equal quarterly installments, commencing on October 31, 2024. The amortization payments due upon such redemption are payable in cash at 107% of the applicable Installment Amount (as defined in the Series C Certificate of Designations).
The holders of the Series C Preferred Shares are entitled to dividends of 5% per annum, compounded quarterly, which will be payable in cash. Upon the occurrence and during the continuance of a Triggering Event (as defined in the Series C Certificate of Designations), the Series C Preferred Shares will accrue dividends at the rate of 15% per annum. The holders of Series C Preferred Shares are entitled to vote with holders of the Common Stock as a single class on all matters that holders of Common Stock are entitled to vote upon, with the number of votes per Series C Preferred Share equal to the stated value of such Series C Preferred Share divided by the “Minimum Price” (as defined in Rule 5635 of the Rule of the Nasdaq Stock Market) immediately prior to the date of the Series C Purchase Agreement.
Following the first anniversary of the initial issuance of the Series C Preferred Shares through the date that is ten calendar days thereafter, holders of Series C Preferred Shares may require the Company to redeem all or any portion of their Series C Preferred Shares in cash, pursuant to the terms set forth in the Series C Certificate of Designation.
The Company received Nasdaq Stockholder Approval at the Company’s special meeting of stockholders held on December 6, 2024.
The Series C Certificate of Designations includes certain Triggering Events (as defined in the Series C Certificate of Designations), including, among other things, the failure to file and maintain an effective registration statement covering the sale of the holder’s securities registrable pursuant to the Series C Registration Rights Agreement (defined below) and our failure to pay any amounts due to the holders of the Series C Preferred Shares when due. In connection with a Triggering Event, each holder of Series C Preferred Shares will be able to require us to redeem in cash any or all of the holder’s Series C Preferred Shares at a premium set forth in the Series C Certificate of Designations.
We are subject to certain affirmative and negative covenants regarding the incurrence of indebtedness, acquisition and investment transactions, the existence of liens, the repayment of indebtedness, the payment of cash in respect of dividends (other than dividends pursuant to the Series C Certificate of Designations), distributions or redemptions, and the transfer of assets, among other matters.
The Series C Warrants are exercisable immediately at the Series C Exercise Price and expire five years from the date of issuance. The Series C Exercise Price is subject to customary adjustments for stock dividends, stock splits, reclassifications and the like, and subject to price-based adjustment, on a “full ratchet” basis, in the event of any issuances of Common Stock, or securities convertible, exercisable or exchangeable for Common Stock, at a price below the then-applicable Series C Exercise Price (subject to certain exceptions). There is no established public trading market for the Series C Warrants and we do not intend to list the Series C Warrants on any national securities exchange or nationally recognized trading system.
In connection with the Series C Purchase Agreement, on September 10, 2024, we and the Series C Investors entered into a Registration Rights Agreement, pursuant to which we were required to file a resale registration statement with the SEC to register for resale 200% of the Unregistered Conversion Shares and 200% of the Series C Warrant Shares. We filed a registration statement for the resale of such securities on October 10, 2024, which was declared effective by the SEC on October 21, 2024. We also agreed to other customary obligations regarding registration, including indemnification and maintenance of the effectiveness of the registration statement.
During the three months ended March 31, 2025, we redeemed $715,000 of the Series C Preferred Stock and $53,563 of accrued dividends in cash through installment redemptions and relieved $1,086,984 of discount related to the redeemed Series C Preferred Stock. During the three months ended March 31, 2025, we recognized a deemed dividend of $53,799 related to cash premiums.
As of March 31, 2025, we have accrued a liability for installment payments owed to investors in either cash or shares of $0.
During the year ended December 31, 2024, we redeemed $715,000 of the Series C Preferred Stock and $86,694 of accrued dividends in cash through installment redemptions and proportionately relieved $1,592,341 of discount related to the redeemed Series C Preferred Stock. During the year ended December 31, 2024, we recognized a deemed dividend of $52,447 related to cash premiums.
Recent Developments
Exploring Strategic Alternatives
In December 2024, we announced via press release that the board of directors of the Company (the “Board “) had formed an independent special committee (the “Special Committee “) to explore strategic opportunities to create and enhance value for investors, including promising drug development platforms and/or compelling new technologies and services. Management has reviewed the Company’s financial position and has concluded that the Company’s continuing financial strength offset by anticipated future cash burn rate and publicly traded stock as currency allows the Special Committee to evaluate potential strategic opportunities.
Other Development Projects
To the extent resources permit, we may pursue development of selected technology platforms with indications related to the treatment of various disorders, including neurodegenerative disorders such as AD, based on our currently licensed technology and/or technologies available from third party licensors or collaborators.
Nemours Agreement
On September 5, 2018, we announced a collaboration with Nemours, a premier U.S. children’s hospital, to initiate a clinical trial in children with Fragile X. In addition to the primary objective of safety and tolerability, measurements will be made of working memory, language and other functional aspects such as anxiety, repetitive behavior, executive functioning, and social behavior. On August 5, 2021, we announced our memorandum of understanding with Nemours A.I. DuPont Hospital (“Nemours”) to initiate a clinical trial using Bryostatin-1, under Orphan Drug Status, to treat Fragile X. We intend to provide the Bryostatin-1 drug product candidate and obtain the IND and Nemours intends to provide the clinical site and attendant support for the trial. We and Nemours, jointly, will develop the trial protocol. We currently estimate our total trial and IND cost to be approximately $2 million. As of the end of the period covered by this quarterly report, we have incurred cumulative expenses associated with this agreement of approximately $100,000.
We have filed for an IND with the FDA. The FDA has placed the development of the IND on clinical hold pending completion of further analytics relating to drug pharmacokinetics and pharmacodynamics. We are currently evaluating our plans to advance Fragile X development.
Cleveland Clinic
On February 23, 2022, we announced our collaboration with Cleveland Clinic to pursue possible treatments for MS, and on July 19, 2023, we announced that we had entered into an agreement with Cleveland Clinic to conduct a Phase 1 trial of Bryostatin-1 in MS. Cleveland Clinic will manage the clinical trial’s implementation, including an IND submission to the FDA and patient enrollment. Cleveland Clinic has enrolled three subjects and has dosed two to - date, with the total planned enrollment in the MS Trial of 20 subjects. The total estimated costs associated with this collaboration are approximately $2.0 million. As of March 31, 2025, we have incurred expenses due to Cleveland Clinic approximately $743,000 of which $215,459 was expensed during the three months ended March 31, 2025.
In December 2024, the Company announced via press release the termination of its agreement with the Cleveland Clinic due to the slow pace of enrollment in the Phase 1 clinical trial. The termination of the agreement was one of various actions authorized by the Board, designed to reduce the Company’s cash burn rate.
Results of Operations
Comparison of the three months ended March 31, 2025 and 2024
The following table summarizes our results of operations for the three months ended March 31, 2025 and 2024:
| Operating Expenses: | | Three Months ended March 31, 2025 | | 2024 | | Dollar Change | | % Change |
|---|---|---|---|---|---|---|---|---|
| Research and development expenses | | $60,816 | | $609,249 | | $(548,433) | | (90.0)% |
| General and administrative expenses | | $1,008,349 | | $1,082,245 | | $(73,896) | | (6.8)% |
| Other income, net | | $(1,454,334) | | $(1,484,795) | | $30,461 | | (2.1)% |
| Net income (loss) | | $385,169 | | $(206,699) | | $591,868 | | 283.6% |
| Net comprehensive income (loss) attributable to common stockholders | | $167,836 | | $(425,858) | | $593,694 | | 139.4% |
Revenues
We did not generate any operating revenues for the three months ended March 31, 2025 and 2024.
Operating Expenses
Overview
Total operating expenses for the three months ended March 31, 2025 were $1,069,165 as compared to $1,691,494 for the three months ended March 31, 2024, a decrease of approximately 36.8%. The decrease in total operating expenses is due to the decrease in both research and development and general and administrative expenses.
Research and Development Expenses
For the three months ended March 31, 2025, we incurred $60,816 in research and development expenses as compared to $609,249 for the three months ended March 31, 2024, a decrease of approximately 90.0%. These expenses were incurred primarily in connection with developing the potential AD therapeutic product and the MS trial with Cleveland Clinic during the three months ended March 31, 2024. Of these expenses, for the year ended three months ended March 31, 2025, $19,839 was incurred principally relating to our storage of drug product, $19,177 for clinical consulting services, $7,425 of amortization of prepaid licensing fees relating to the Stanford License Agreement and Mount Sinai Agreement, and $14,375 for development of alternative drug supply with Stanford University; comparatively, for the three months ended March 31, 2024, $421,823 was incurred principally relating to our confirmatory clinical trial and related storage of drug product, $170,444 for clinical consulting services, $7,104 of amortization of prepaid licensing fees relating to the Stanford License Agreement and Mount Sinai Agreement, and $9,878 for development of alternative drug supply with Stanford University.
Our research and development expenses have decreased as our Phase 2 clinical trial for AD was concluded by the end of 2023 and our Phase 2 dose ranging study and our MS clinical trial were discontinued. Other development expenses might increase, as our resources permit, in order to advance our potential products. We are continuing to determine how to proceed with respect to our other current development programs for Bryostatin-1.
General and Administrative Expenses
We incurred $1,008,349 and $1,082,245 of general and administrative expenses for the three months ended March 31, 2025 and 2024, respectively, a decrease of approximately 6.8%. During the three months ended March 31, 2025, $237,242 was incurred primarily for wages, bonuses, vacation pay, severance, taxes and insurance, versus $342,659 for the three months ended March 31, 2024, the decrease resulted primarily from compensation reductions for our President and our Chief Executive Officer; $78,447 was incurred for legal expenses versus $113,656 for the 2024 comparable period. The higher legal fees for 2024 is based upon the prior year’s increased fees for special stockholder meeting requirements and for regulatory compliance; $194,358 was incurred for outside operations consulting services during the three months ended March 31, 2025, versus $262,002 for the comparable period in 2024, as the lower amount for the 2025 period reflects the decrease in regulatory and compliance work; $15,959 was incurred for travel expenses during the three months ended March 31, 2025, versus $34,881 for the comparable period in 2024 as Company officers and directors conducted overseas due diligence for strategic investments in 2024; $149,961 was incurred for investor relations services during the three months ended March 31, 2025, versus $164,732 for the comparable period in 2024; $89,746 was incurred for professional fees associated with auditing, financial, accounting and tax advisory services during the three months ended March 31, 2025, versus $20,713 for the comparable period in 2024, the increase was attributable to year end 2024 audit services paid during the current 2025 quarter; $130,204 was incurred for insurance during the three months ended March 31, 2025, versus $154,965 for the comparable period in 2024. The decrease is attributable to lower premiums; $108,724 was incurred for utilities, supplies, license fees, filing costs, rent, advertising and other during the three months ended March 31, 2025, versus $(25,771) for the comparable period in 2024. The increase is attributable to credits for lower franchise taxes paid during the 2024 period credited to 2024; and $3,709 was recorded as non-cash stock options compensation expense during the three months ended March 31, 2025, versus $14,407 for the comparable period in 2024.
Other Income
We recognized total other income of $1,454,334 for the three months ended March 31, 2025 as compared to total other income of $1,484,795 for the three months ended March 31, 2025, which consisted, for 2025 and 2024, of interest income on funds deposited in interest-bearing money market accounts and investments in short-term U.S. treasury bills and changes in fair value of warrant and derivative liabilities and offering costs. The decrease in interest income and unrealized gains on treasury bills totaling $281,061 for the three months ended March 31, 2025 is primarily attributable to the decrease in cash balances over the period and lower interest rates. The total decrease in other income is primarily attributable to the decrease in interest income as noted above, in and the decrease in change in fair value of derivative liability of $1,051,000, partially offset by the change in fair value of derivative liability of $1,293,000 and the decrease in net loss in equity investment of $8,600.
Net income (loss)
We recognized income of $385,169 versus a loss of ($206,699) for the three months ended March 31, 2025 and 2024, respectively. The increased income was primarily attributable to the decrease in research and development and general and administrative expenses partially offset by the decrease in other income.
Financial Condition, Liquidity and Capital Resources
Cash and Working Capital
Since inception, we have incurred negative cash flows from operations. As of March 31, 2025, we had working capital of $15,106,751 as compared to working capital of $16,706,587 as of December 31, 2024. The $1,599,836 decrease in working capital was primarily attributable to approximately $1.0 million of operating expenses, redemption of Series C Preferred Stock of approximately $800,000 partially offset by and interest income of approximately $0.2 million.
We expect that our current cash and cash equivalents of approximately $13.8 million will be sufficient to support our projected operating requirements for at least the next 12 months from the date of this Quarterly Report on Form 10-Q, which may include the continuing development of Bryostatin-1 for neurodegenerative diseases.
We expect to require additional capital in order to initiate, pursue and complete all potential clinical trials and obtain regulatory approval of one or more therapeutic candidates. However, additional future funding may not be available to us on acceptable terms, or at all. If we are unable to access additional funds when needed, we may not be able to initiate, pursue and complete all planned clinical trials or continue the development of our product candidates or we could be required to delay, scale back or eliminate some or all of our development programs and operations. Any additional equity financing, if available, may not be available on favorable terms, would most likely be significantly dilutive to our current stockholders and debt financing, if available, and may involve restrictive covenants. If we are able to access funds through collaborative or licensing arrangements, we may be required to relinquish rights to some of our technologies or product candidates that we would otherwise seek to develop or commercialize on our own, on terms that are not favorable to us. Our ability to access capital when needed is not assured and, if not achieved on a timely basis, would likely materially harm our business and financial condition.
Sources and Uses of Liquidity
We expect to continue to incur expenses, resulting in losses and negative cash flows from operations, over at least the next several years as we continue to develop AD and other therapeutic products. We anticipate that this development may include clinical trials in addition to our current ongoing clinical trial and additional research and development expenditures.
| | | Three Months Ended March 31, 2025 | | 2024 |
|---|---|---|---|---|
| Cash used in operating activities | | $2,000,596 | | $1,831,541 |
| Cash used in investing activities | | $— | | $500,000 |
| Cash used in financing activities | | $822,362 | | $— |
Net Cash Used in Operating Activities
Cash used in operating activities was $2,000,596 for the three months ended March 31, 2025, compared to $1,831,541 for the three months ended March 31, 2024. The $169,055 increase primarily resulted from the increase in non-cash expenses and change in fair value of liabilities of approximately $0.3 million, the decrease in prepaid expenses of approximately $0.3 million and the decrease in accounts payable and accrued expenses of totaling approximately $0.2 million partially offset by the increase in net income of approximately $0.6 million.
Net Cash Used in Investing Activities
Net cash used in investing activities was $0 for the three months ended March 31, 2025 compared to $500,000 for the three months ended March 31, 2024. The cash used in investing activities for the three months ended March 31, 2024 was for the purchase of available for sale debt securities.
Net Cash Used in Financing Activities
Net cash used in financing activities was $822,362 for the three months ended March 31, 2025 compared to $0 for the three months ended March 31, 2024. The cash used in financing activities for the three months ended March 31, 2025 consisted of redemptions and dividends of amounts due to preferred stock investors.
Controls and procedures
As filed, 3,370 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
We carried out an evaluation under the supervision and with the participation of our management, including our principal executive officer and our principal financial and accounting officer, of the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. Based on their evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures are not effective due to: inadequate segregation of duties consistent with control objectives in the areas over certain payroll and banking systems and user access controls; ineffective processes over period end financial disclosure and reporting including documentation of GAAP disclosure and reporting reviews supporting the financial reporting process and changes to chart of accounts; and ineffective information technology (IT) general computing controls including lack of risk and design assessments supporting IT security policies and procedures, user access, and IT controls within third party contracts. These weaknesses may affect management’s ability to determine if errors or inappropriate actions have taken place. Management is required to apply its judgment in evaluating the cost-benefit relationship of possible changes in our disclosure controls and procedures.
We previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, that our management, including our Chairman of the Board, principal executive officer and principal financial and accounting officer, assessed the effectiveness of our internal control over financial reporting based on the criteria for effective internal control over financial reporting established in the 2013 Internal Control— Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) and SEC guidance on conducting such assessments. Based on that evaluation, they concluded that, during the period covered by the Annual Report on Form 10-K for the fiscal year ended December 31, 2024, such internal controls and procedures were not effective to detect the inappropriate application of US generally accepted accounting principles.
Based on management’s review, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were ineffective as of March 31, 2025. Notwithstanding the material weaknesses described above, our management, including the Chief Executive Officer and Chief Financial Officer, has concluded that financial statements, and other financial information included in this Quarterly Report on Form 10-Q, fairly present in all material respects our financial condition, results of operations, and cash flows as of and for the periods presented in this Quarterly Report on Form 10-Q.
Changes in Internal Controls over Financial Reporting
There was no change in our internal controls over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q, which has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.
PART II
OTHER INFORMATION
Risk factors
As filed, 481 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
You should carefully review and consider the information regarding certain factors that could materially affect our business, consolidated financial condition or results of operations set forth under Item 1A. Risk Factors in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. There have been no material changes from the risk factors disclosed in such Form 10-K. We may disclose changes to risk factors from time to time in our future filings with the SEC.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2025-01-01 to 2025-03-31 | $60.8k | us-gaap:ResearchAndDevelopmentExpense |
| Net income | 3 months2025-01-01 to 2025-03-31 | $385.2k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-01-01 to 2025-03-31 | $0.04 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-01-01 to 2025-03-31 | $0.12 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-01-01 to 2025-03-31 | 1,392,881 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2025-01-01 to 2025-03-31 | −$2.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2025-03-31 | $14.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-03-31 | $15.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-03-31 | $15.3m | us-gaap:Assets |
| Current liabilities | At period end2025-03-31 | $210.7k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-03-31 | $8.9m | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-03-31 | $5.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001410578-25-001327. Last ingested by Listed: Nov 2, 2026, 06:08 ET. Listed shows no prices and gives no investment advice.